Skip to content
ES
MARKETS / NASDAQ / MGNX
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Macrogenics Inc. MGNX

15 fiscal years on record · USD · FY2025 reported · SEC filings only
$149.5M
▼ 0.3% YoY
$-74.6M
$-83.0M
In brief

What this company does

It has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets the checkpoint inhibitors PD-1 and CTLA-4; MGC026, an antibody-drug conjugate that targets B7-H3; and MGC028, an antibody-drug conjugate that targets ADAM9. It has an FDA-approved commercial manufacturing site in Rockville, Maryland, where it commercially produces MARGENZA and ZYNYZ drug substance for TerSera and Incyte, respectively. As of February 28, 2026, it had 293 full-time employees, 245 of whom were primarily engaged in research, development and manufacturing activities. Since its inception in 2000, its collaborations have provided it with over $1.6 billion of non-dilutive funding.

Written from the business description in MACROGENICS INC's annual report to the U.S. Securities and Exchange Commission, filed 9 March 2026. Every sentence was checked against that document before publication.

Growth
USD 149.5M
Revenue, FY2025 · full 15-year series below
Revenue $M Net income $M
FY2025 · Revenue 149.5 · Net income -74.6
80M-80M-160M20112013201520172019202120232025
Compound annual growth
−0.5%
+7.3%
+4.0%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +7.3% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−50 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -48.7% · Net -49.9%
-100%-200%20112013201520172019202120232025
ROE
FY2025 · ROE -86.9%
-50%20112013201520172019202120232025
Gross margin100.0%
Operating margin-48.7%
Net margin-49.9%
Return on assets-28.8%
EBITDAUSD -65.7M

Each USD of equity lost 87 cents this year.

Cash & shareholders
—
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -83.0
-80M-160M20112013201520172019202120232025
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—

Total assetsUSD 256.8M
EquityUSD 55.6M
CashUSD 57.2M
Current ratio5.10×

Equity funds 22% of total assets.

The 15-year record
15 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020201920182017201620152014201320122011
Revenue $B0.10.10.10.20.10.10.10.10.20.10.10.00.10.10.1
Operating income $B−0.1−0.1−0.2−0.1−0.2−0.1−0.2−0.2−0.0−0.1−0.0−0.00.00.00.0
EBITDA $B−0.1−0.1−0.2−0.1−0.2−0.1−0.2−0.2−0.0−0.1−0.0−0.00.00.00.0
Income tax $B−0.00.00.00.00.00.00.00.00.00.00.00.00.00.0·
Net income $B−0.1−0.1−0.0−0.1−0.2−0.1−0.2−0.2−0.0−0.1−0.0−0.0−0.00.00.0
Free cash flow $B−0.1−0.1−0.1−0.1−0.2−0.1−0.1−0.2−0.0−0.1−0.0−0.0−0.0−0.00.0
EPS, diluted $−1.18−1.07−0.15−1.95−3.37−2.47··−0.54−1.69−0.63−1.40−0.040.000.00
Dividend / sh $···············
Payout %···············
ROE %−86.9−49.9−6.1−62.8−75.5−49.3−64.1−63.3−6.9−20.1−9.3−38.3−0.7··
Shares out B0.060.060.060.060.060.060.050.040.040.030.030.030.030.00·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 54 reconciliationsAUDITED

Reconciled in 15 of 19 fiscal years. 34 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2011

Share this section

Download image